Paclitaxel Actavis 6 mg/ml koncentrat till infusionsvätska

DRUG2 trials

Sponsors

Karolinska University Hospital, F. Hoffmann-La Roche AG

Conditions

Non-metastatic HER2-positive Breast CancerPersistent or Recurrent Rare Epithelial Ovarian Tumors

Phase 2

A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

RecruitingCTIS2022-501504-95-00

Karolinska University HospitalNon-metastatic HER2-positive Breast Cancer

Start: 2023-06-23Target: 402Updated: 2025-08-18

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruitingCTIS2023-508194-89-00

F. Hoffmann-La Roche AGPersistent or Recurrent Rare Epithelial Ovarian Tumors

Start: 2021-08-30Target: 57Updated: 2026-01-06

Related Papers

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

BMJ Open2025-08-011 citations

Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.

2025-03-073 citations